disulfiram has been researched along with Cancer of Lung in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 5.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| "Disulfiram (DSF) has copper (Cu)-dependent anticancer properties in vitro and in vivo." | 5.48 | Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways. ( Li, TY; Li, Y; Liu, S; Wang, LH; Wang, YT; Wu, CF; Yang, JY; Yuan, XZ; Zhang, HT; Zhou, WL, 2018) |
| "Here we investigated malignant pleural mesothelioma (MPM) suppressive effects of DSF-Cu and the molecular mechanisms involved." | 5.40 | Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis. ( Chen, D; Cheriyan, VT; Dou, QP; Jamal, S; Muthu, M; Pass, HI; Polin, LA; Rishi, AK; Sharma, S; Tarca, AL; Wali, A; Wang, Y; Yang, H, 2014) |
| "Disulfiram is an inexpensive and safe drug; if its addition to chemotherapy could be shown to prolong survival, an effective regimen could be established and used widely, even in resource-poor countries." | 2.80 | A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. ( Baron, A; Gotfried, M; Hamamreh, Y; Nechushtan, H; Nidal, S; Nisman, B; Peretz, T; Peylan-Ramu, N; Shalev, YI, 2015) |
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 1.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| "Disulfiram (DSF) has copper (Cu)-dependent anticancer properties in vitro and in vivo." | 1.48 | Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways. ( Li, TY; Li, Y; Liu, S; Wang, LH; Wang, YT; Wu, CF; Yang, JY; Yuan, XZ; Zhang, HT; Zhou, WL, 2018) |
| "Disulfiram (DSF) is an approved drug for the treatment of alcohol dependence, but has also been shown to kill TNBC cells in a copper (Cu)-dependent manner." | 1.46 | Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. ( An, H; Cho, TM; Cho, Y; Kim, JY; Kim, YJ; Lee, N; Oh, E; Seo, JH; Sung, D, 2017) |
| "Disulfiram (DSF), which has multi-targeted anti-tumor activity, was encapsulated into redox-sensitive shell crosslinked micelles to achieve intracellular targeted delivery and finally inhibit tumor growth and metastasis." | 1.40 | Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. ( Duan, X; Li, Y; Mao, S; Xiao, J; Yin, Q; Yu, H; Zhang, Z, 2014) |
| "Here we investigated malignant pleural mesothelioma (MPM) suppressive effects of DSF-Cu and the molecular mechanisms involved." | 1.40 | Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis. ( Chen, D; Cheriyan, VT; Dou, QP; Jamal, S; Muthu, M; Pass, HI; Polin, LA; Rishi, AK; Sharma, S; Tarca, AL; Wali, A; Wang, Y; Yang, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.81) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Kryczka, J | 2 |
| Janczewski, Ł | 1 |
| Gajda, A | 1 |
| Frączyk, A | 1 |
| Boncela, J | 1 |
| Kolesińska, B | 1 |
| Brzeziańska-Lasota, E | 1 |
| Yuan, XX | 1 |
| Duan, YF | 1 |
| Luo, C | 1 |
| Li, L | 1 |
| Yang, MJ | 1 |
| Liu, TY | 1 |
| Cao, ZR | 1 |
| Huang, W | 1 |
| Bu, X | 1 |
| Yue, X | 1 |
| Liu, RY | 1 |
| Bagherpoor, AJ | 1 |
| Shameem, M | 1 |
| Luo, X | 1 |
| Seelig, D | 1 |
| Kassie, F | 1 |
| Wang, N | 2 |
| Zhu, D | 1 |
| Liu, Y | 2 |
| Wu, J | 1 |
| Wang, M | 1 |
| Jin, S | 1 |
| Fu, F | 1 |
| Li, B | 1 |
| Ji, H | 1 |
| Du, C | 1 |
| Zheng, Z | 1 |
| Terashima, Y | 1 |
| Toda, E | 1 |
| Itakura, M | 1 |
| Otsuji, M | 1 |
| Yoshinaga, S | 1 |
| Okumura, K | 1 |
| Shand, FHW | 1 |
| Komohara, Y | 1 |
| Takeda, M | 1 |
| Kokubo, K | 1 |
| Chen, MC | 1 |
| Yokoi, S | 1 |
| Rokutan, H | 1 |
| Kofuku, Y | 1 |
| Ohnishi, K | 1 |
| Ohira, M | 1 |
| Iizasa, T | 1 |
| Nakano, H | 1 |
| Okabe, T | 1 |
| Kojima, H | 1 |
| Shimizu, A | 1 |
| Kanegasaki, S | 1 |
| Zhang, MR | 1 |
| Shimada, I | 1 |
| Nagase, H | 1 |
| Terasawa, H | 1 |
| Matsushima, K | 1 |
| Lu, X | 1 |
| Lin, B | 1 |
| Xu, N | 1 |
| Huang, H | 1 |
| Wang, Y | 4 |
| Lin, JM | 1 |
| Li, Y | 4 |
| Wang, LH | 2 |
| Zhang, HT | 1 |
| Wang, YT | 2 |
| Liu, S | 1 |
| Zhou, WL | 1 |
| Yuan, XZ | 2 |
| Li, TY | 1 |
| Wu, CF | 2 |
| Yang, JY | 2 |
| Wang, NN | 1 |
| Fu, SY | 1 |
| Xue, X | 2 |
| Jia, LN | 1 |
| Tang, X | 1 |
| Bucci, M | 1 |
| Mohammad, IS | 1 |
| He, W | 1 |
| Yin, L | 1 |
| Wu, X | 1 |
| Wang, L | 2 |
| Wang, W | 2 |
| Han, J | 1 |
| Sun, X | 1 |
| Zhang, H | 1 |
| Che, X | 1 |
| Yang, J | 3 |
| Wu, C | 2 |
| Chen, X | 1 |
| Yang, Q | 1 |
| Chen, J | 2 |
| Zhang, P | 1 |
| Huang, Q | 1 |
| Zhang, X | 2 |
| Yang, L | 1 |
| Xu, D | 1 |
| Zhao, C | 1 |
| Wang, X | 1 |
| Liu, J | 1 |
| Duan, X | 1 |
| Xiao, J | 1 |
| Yin, Q | 1 |
| Zhang, Z | 1 |
| Yu, H | 1 |
| Mao, S | 1 |
| Duan, L | 1 |
| Shen, H | 1 |
| Zhao, G | 1 |
| Yang, R | 1 |
| Cai, X | 1 |
| Zhang, L | 1 |
| Jin, C | 1 |
| Huang, Y | 1 |
| Cheriyan, VT | 1 |
| Muthu, M | 1 |
| Jamal, S | 1 |
| Chen, D | 1 |
| Yang, H | 1 |
| Polin, LA | 1 |
| Tarca, AL | 1 |
| Pass, HI | 1 |
| Dou, QP | 1 |
| Sharma, S | 1 |
| Wali, A | 1 |
| Rishi, AK | 1 |
| Nechushtan, H | 1 |
| Hamamreh, Y | 1 |
| Nidal, S | 1 |
| Gotfried, M | 1 |
| Baron, A | 1 |
| Shalev, YI | 1 |
| Nisman, B | 1 |
| Peretz, T | 1 |
| Peylan-Ramu, N | 1 |
| Liu, X | 1 |
| Cui, W | 1 |
| Yuan, X | 1 |
| Lin, L | 1 |
| Cao, Q | 1 |
| Guo, W | 1 |
| Kim, JY | 1 |
| Lee, N | 1 |
| Kim, YJ | 1 |
| Cho, Y | 1 |
| An, H | 1 |
| Oh, E | 1 |
| Cho, TM | 1 |
| Sung, D | 1 |
| Seo, JH | 1 |
| Najlah, M | 1 |
| Ahmed, Z | 1 |
| Iqbal, M | 1 |
| Wang, Z | 1 |
| Tawari, P | 1 |
| McConville, C | 1 |
| Wang, C | 1 |
| Han, H | 1 |
| Li, Q | 1 |
| O'Brien, A | 1 |
| Barber, JE | 1 |
| Reid, S | 1 |
| Niknejad, N | 1 |
| Dimitroulakos, J | 1 |
| Epstein, SS | 1 |
| Joshi, S | 1 |
| Andrea, J | 1 |
| Forsyth, J | 1 |
| Mantel, N | 1 |
| Habs, M | 1 |
| Schmähl, D | 1 |
| Kretzer, H | 1 |
| Balansky, RM | 1 |
| Marikovsky, M | 1 |
| Nevo, N | 1 |
| Vadai, E | 1 |
| Harris-Cerruti, C | 1 |
| Kitson, TM | 1 |
| Wattenberg, LW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine[NCT00312819] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for disulfiram and Cancer of Lung
| Article | Year |
|---|---|
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
26 other studies available for disulfiram and Cancer of Lung
| Article | Year |
|---|---|
Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene-Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Benzene; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2022 |
Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation | 2023 |
Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung | 2023 |
NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disulfiram; Humans; Lung; Lung Neoplasms; | 2023 |
Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties.
Topics: Animals; Cell Proliferation; Chemokines; Clathrin Heavy Chains; Disease Progression; Disulfiram; Dru | 2020 |
Evaluation of the accumulation of disulfiram and its copper complex in A549 cells using mass spectrometry.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Copper; Disulfiram; Di | 2020 |
Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Copper; Disulfiram; Down-Regula | 2018 |
Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Topics: A549 Cells; Aldehyde Dehydrogenase, Mitochondrial; Animals; Carcinoma, Non-Small-Cell Lung; Cell Lin | 2018 |
Cancer therapy: A path of DSF destruction.
Topics: Carcinoma, Non-Small-Cell Lung; Disulfiram; Humans; Illicit Drugs; Lung Neoplasms | 2018 |
A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Disulfi | 2018 |
Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tum | 2018 |
Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumo | 2018 |
Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cel | 2014 |
Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.
Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Disulfiram; Gene Expression Reg | 2014 |
Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Carcinoma, Non-Small-Cell Lung; Ce | 2016 |
Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
Topics: Animals; Anoikis; Antineoplastic Agents; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2017 |
Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disulfiram; Humans; Lactic Acid; Lung Neoplasms; M | 2017 |
Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer.
Topics: Administration, Inhalation; Alcohol Deterrents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; C | 2017 |
Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
The null effect of antioxidants on the carcinogenicity of 3, 4, 9, 10-dibenzpyrene to mice.
Topics: Aniline Compounds; Animals; Antioxidants; Benzopyrenes; Butyrophenones; Carcinogens; Disulfiram; Fib | 1967 |
Effect of disulfiram on acetoxymethyl-methyl-nitrosamine-induced tumors in rats.
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Dimethylnitrosamine; Disulfiram; Ear Neoplasms; F | 1981 |
Effects of cigarette smoke and disulfiram on tumorigenicity and clastogenicity of ethyl carbamate in mice.
Topics: Animals; Bone Marrow; Cytochrome P-450 Enzyme System; Disulfiram; Female; Lung Neoplasms; Male; Mice | 1995 |
Cu/Zn superoxide dismutase plays a role in angiogenesis.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Disulfiram; Endothelium, Vascular; Enzym | 2002 |
Disulfiram and cigarettes.
Topics: Acetaldehyde; Disulfiram; Ditiocarb; Drug Interactions; Humans; Lung Neoplasms; Smoking | 1978 |
Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by several sulfur-containing compounds.
Topics: Adenoma; Administration, Oral; Adrenal Glands; Aldehyde Oxidoreductases; Animals; Benz(a)Anthracenes | 1974 |